Desbuards Nicolas, Rochefort Gaël Y, Schlecht Deborah, Machet Marie-Christine, Halimi Jean-Michel, Eder Véronique, Hyvelin Jean-Marc, Antier Daniel
LABPART - EA 3852 - IFR135 - Université François Rabelais, Tours Cedex 1, France.
Thromb Haemost. 2007 Sep;98(3):614-20.
Hemin is a heme oxygenase-1 (HO-1) inducer which provides endogenous carbon monoxide known for playing roles in cell proliferation, inflammation or aggregation process. The objective of the current study was to examine the effect of prophylactic treatment with hemin in a thrombosis vascular model. Three groups of Wistar rats, control (n = 6), hemin (n = 6) and hemin + HO-1 inhibitor (n = 6), were used for this study. Hemin-treated animals received hemin (50 mg/kg/d; I.P.) for seven days and HO-1 inhibitor group received hemin at the same dose and SnPP IX (60 mg/kg/d; I.P.). All animals were exposed to electric stimulation of the left carotid according to Kawasaki's procedure to induce reproducible thrombus formation. The hemin treatment did not induce blood pressure disturbance. Effects of hemin on vascular thrombosis were quantified by histopathology and its influence on haemostasis was assessed by measuring prothrombin time (PT), activated partial thromboplastin time (APTT) and blood parameters at the end of treatment. The HO-1 mRNA and protein level variation were also checked out. Results showed that chronic treatment with hemin significantly (p < 0.01) reduced the vascular occlusion degree when compared to control and hemin SnPP groups with 7.2 +/- 4.6 vs. 71.1 +/- 14.7 and 74.0 +/- 8.8%, respectively. Moreover, we observed significant (p < 0.05) perturbations of blood parameters in hemin-treated and hemin-SnPP treated rats. Interestingly, hemin treatment did not significantly increase both PT and APTT. Finally, the HO-1 mRNA and protein levels were increased in hemin-treated carotid artery. In conclusion, hemin by inducing HO-1 expression may be a preventive agent against clinical disorders associated to an increased risk of thrombosis events and may limit haemorrhagic risks.
血红素是一种血红素加氧酶-1(HO-1)诱导剂,可提供内源性一氧化碳,已知其在细胞增殖、炎症或聚集过程中发挥作用。本研究的目的是在血栓形成血管模型中研究血红素预防性治疗的效果。本研究使用了三组Wistar大鼠,即对照组(n = 6)、血红素组(n = 6)和血红素+HO-1抑制剂组(n = 6)。接受血红素治疗的动物连续7天腹腔注射血红素(50 mg/kg/d),HO-1抑制剂组接受相同剂量的血红素和锡原卟啉IX(SnPP IX,60 mg/kg/d;腹腔注射)。根据川崎氏方法,对所有动物的左颈动脉进行电刺激,以诱导可重复性血栓形成。血红素治疗未引起血压紊乱。通过组织病理学对血红素对血管血栓形成的影响进行定量,并在治疗结束时通过测量凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和血液参数来评估其对止血的影响。同时还检测了HO-1 mRNA和蛋白水平的变化。结果显示,与对照组和血红素+SnPP组相比,血红素长期治疗显著(p < 0.01)降低了血管闭塞程度,分别为7.2±4.6%、71.1±14.7%和74.0±8.8%。此外,我们观察到接受血红素治疗和血红素+SnPP治疗的大鼠血液参数有显著(p < 0.05)扰动。有趣的是,血红素治疗并未显著增加PT和APTT。最后,血红素治疗的颈动脉中HO-1 mRNA和蛋白水平升高。总之,血红素通过诱导HO-1表达可能是一种预防与血栓形成事件风险增加相关临床疾病的药物,并且可能限制出血风险。